Massimo Group Reports Third Quarter 2024 Financial Results

Year-to-Date 2024 Revenue Increases 20.8% YoY to $91.2 Million

New Production, Product and Sales Initiatives Driving Motor Vehicle Growth

GARLAND, Texas, Nov. 15, 2024 /PRNewswire/ — Massimo Group MAMO (“Massimo”), a manufacturer and distributor of powersports vehicles and pontoon boats, has reported its financial and operational results for the third quarter ended September 30, 2024.

Key Financial Q3 2024 and Subsequent Operational Highlights and Business Updates

($ millions)

Nine Month Comparison


Q3 Comparison


9M 2024

9M 2023

$ Change
YoY

% Change
YoY


Q3 2024

Q3 2023

$ Change
YoY

% Change
YoY

Revenue

$91.2

$75.5

$15.7

20.8 %


$25.6

$29.9

($4.3)

(14.4 %)

Gross Profit

$28.9

$23.8

$5.1

21.6 %


$7.0

$10.1

($3.1)

(30.9 %)

Gross Margin

31.7 %

31.5 %

21 bps



27.2 %

33.6 %

 (647) bps


Net Income

$3.5

$6.6

($3.1)

(46.9 %)


($2.5)

$4.0

($6.5)

(163.2 %)

  • 9M 2024 revenue increased 20.8% to $91.2 million compared to $75.5 million in 9M 2023.
  • 9M 2024 gross profit increased 21.6% to $28.9 million from $23.8 million in 9M 2023. Gross margin increased 21 basis points to 31.7% in 9M 2024 from 31.5% in 9M 2023.
  • 9M 2024 net income decreased 46.9% to $3.5 million, or $0.09 per basic and diluted share, as compared to net income of $6.6 million, or $0.16 per basic and diluted share, in 9M 2023.
  • Q3 2024 revenue decreased 14.4% to $25.6 million compared to $29.9 million in Q3 2023.
  • Q3 2024 gross profit decreased 30.9% to $7.0 million from $10.1 million in Q3 2023. Gross margin decreased 647 basis points to 27.2% in Q3 2024 from 33.6% in Q3 2023.
  • Q3 2024 net income decreased 163.2% to a loss ($2.5) million, or ($0.06) per basic and diluted share, as compared to net income of $4.0 million, or $0.10 per basic and diluted share, in Q3 2023.
  • New vehicle launches included:
    • T-Boss UTV series for the winter season with cab enclosure built to deliver complete protection from the elements.
    • T-Boss 1000 UTV, the best equipped and most value-packed UTV in its class with a perfect blend of utility, performance and capability. 
    • GKD 350 All-Terrain Go Kart, combining iconic styling with powerful performance in a rugged two-seater go-kart perfect for conquering any terrain.
  • Exhibited Massimo Motor vehicles at the Equip Exposition, Mid-States Fall Rendezvous 2024, and Outdoor Power Equipment Hoedown for Mid-States Distributing Company, Inc.
  • Announced the adoption of a new automated vehicle assembly robot line to be installed in the third calendar quarter at its 376,000 square foot factory in Garland, Texas to support production of its ATV and UTV vehicles lines.

Management Commentary

“During the third quarter we continued to leverage new product innovation and a strong customer base to drive our strategic business expansion and growth prospects, and solidify our brand’s position in key markets,” said David Shan, Founder, Chairman & CEO. “The third quarter was marked by industry-wide challenges and pressure on Pontoon boat sales, countered by expansions in motor vehicle production, distribution and products that are supporting revenue momentum. An ongoing cadence of new vehicle launches and marketing efforts across the country are driving adoption from new distribution partners and retailers to expand our national footprint. Following the conservatism principle in accounting, we adopted a cautious approach and recorded a one-time charge of approximately $3.6 million in the third quarter due to ongoing litigation, which is currently under appeal. Should there be any favorable ruling in the future, it will result in gains reversing the charge we took in this period. Without this charge the net income for the quarter would have been positive.

“In the last several months we have launched several exciting new vehicles and vehicle series as we continue to invest in our R&D to further enhance our products, using advanced technology to offer our UTV customers a smoother and more comfortable ride. We launched a new feature-rich T-Boss 1000 UTV for those who are looking for a powerful and versatile UTV that can handle any trip, with some specific features that make it a great choice for ranchers, hunters and more. A new series of T-Boss UTVs is equipped with Cab Enclosure that is built to deliver complete protection from the elements. Made with durable tempered glass, this fully enclosed cabin shields passengers from rain, wind, and snow, providing a comfortable environment for all outdoor tasks. Finally, we introduced the new GKD 350 All-Terrain Go Kart, our new rugged two-seater go-kart perfect for conquering any terrain. Built tough with standard safety features, the GKD 350 delivers both endless fun and a utility-driven experience with a 300cc power plant, 25 inch all terrain tires and easy-to-drive automatic transmission. We are now ramping sales of these new products through our sales network nationwide.

“To support these new products and our full lineup of rugged, versatile vehicles, we showcased our vehicles to hundreds of thousands of potential customers at several flagship expos and events around the country. We engaged with several potential new dealers, discussing opportunities that could enhance our distribution network and increase market penetration. These events also serve as an excellent opportunity for us to engage with store partners and discuss potential collaborations, which we believe lays the foundation for future revenue growth.

“Several production initiatives during the quarter are positioning us to further expand output levels each month. A new expansion has added 90,000 sq. ft. to our manufacturing facility in Garland, Texas to support increased production across motor and marine product verticals. At this facility we are also launching a new automated vehicle assembly robot line that are being installed as expected. This automation is expected to improve efficiency by 50% and enhance safety for production of ATV and UTV vehicles lines.

“Looking ahead, we are committed to delivering value as we scale operations and broaden our reach in domestic and international markets. We continue to build manufacturing capacity aimed at enhancing flexibility and increasing annual production, including an automated vehicle assembly robot line and the Armlogi partnership, which are expected to allow us to meet the growing demand of our products. We believe with increased operating efficiencies we can further improve margins while continuing to grow our revenue and expand our product line with new models. We are focusing on driving sales across our existing and new diversified product portfolio. With positive feedback on our new vehicles, we are confident in the growth prospects for the first half of 2025 as the introduction of new products and distribution relationships is expected to present significant opportunities for us to build market share and deliver long-term value to our shareholders,” concluded Mr. Shan.

Third Quarter 2024 Financial Results

For the three months ended September 30, 2024, revenues decreased by $4.3 million, or 14.4%, to $25.6 million, compared to $29.9 million in the prior year period. The decrease in revenue was primarily due to a significant drop in Pontoon boat sales, and a slight decrease in sales of UTV, ATV and e-bikes.

Revenue from sales of UTVs, ATVs and e-bikes decreased by $1.9 million, or 6.9%, from $27.0 million in the third quarter of fiscal 2023, to $25.1 million in the third quarter of fiscal 2024. The decrease in revenue was partially driven by the slow industry-wide trend, and partially by the seasonal promotions we offered in the third quarter of fiscal 2024.

Revenue from sales of Pontoon Boats decreased by $2.4 million, or 82.5%, from $3.0 million in the third quarter of fiscal 2023, to $0.5 million in the third quarter of fiscal 2024. The decrease in revenue was primarily attributable to the significant industry-wide downturn due to the impact of the high interest rates and inflation as demonstrated in the high rejection rates dealers have encountered from floorplan financing providers such as Northpoint. This trend aligns with the industry-wide challenges that intensified in the third quarter of fiscal 2024. Additionally, economic uncertainty in the U.S. has led to reduced spending on luxury boats, further constraining our Pontoon Boat sales.

Gross profit decreased by $3.1 million, or 30.9%, from $10.1 million in the third quarter of fiscal 2023, to $7.0 million in the third quarter of fiscal 2024. The gross profit margin was 27.2% in the third quarter of fiscal 2024, compared with 33.6% in the same period last year. The decrease of 6.5% in the gross profit margin is consistent with (i) reduced sale prices aimed at clearing slow-moving inventory, and (ii) the decline in sales of Pontoon Boats, without a corresponding reduction in fixed overhead costs, such as rent and salaries.

The cost of revenue on UTVs, ATVs and e-bikes increased by $0.6 million, or 3.7%, from $17.5 million in the third quarter of fiscal 2023 to $18.1 million in the third quarter of fiscal 2024, and gross profit decreased by $2.5 million, or 26.5%, from $9.4 million in the third quarter of fiscal 2023 to $6.9 million in the third quarter of fiscal 2024. The gross margin decreased by 7.4%, from 35.1% in the third quarter of fiscal 2023 to 27.7% in the third quarter of fiscal 2024. The increase in the cost of revenue was largely due to higher overhead costs, mainly from research and design input and the additional rent expense as we expand our warehouse space in fiscal 2024. The slight decrease in gross margin was primarily a result of selling some inventory at lower price at our seasonal promotions in the third quarter of fiscal 2024.

The cost of revenue on Pontoon Boats decreased by $1.9 million, or 78.3%, from $2.4 million in the third quarter of fiscal 2023 to $0.5 million in the third quarter of fiscal 2024, and gross profit decreased by $0.6 million, or 98.9%, from $0.6 million in the third quarter of fiscal 2023 to $6,619 in the third quarter of fiscal 2024. The gross margin decreased by 19.1%, from 20.4% in the third quarter of fiscal 2023 to 1.3% in the third quarter of fiscal 2024. The decrease in gross margin was primarily a result of a decline in sales of Pontoon Boats, without a corresponding reduction in fixed overhead costs, such as rent, utilities, and salaries.

Selling expenses increased by $0.5 million, or 24.9%, from $2.1 million in the third quarter of fiscal 2023 to $2.6 million in the third quarter of fiscal 2024. The increase in selling expenses was mainly due to an increase in shipping and handling fees. The increase was partly offset by a decrease in warranty expense of approximately $0.4 million, due to enhanced quality control and customer service measures. The adoption of a traveling technician team has enabled timely responses to customer requests, reducing repair costs.

General and administrative expenses increased by $1.2 million, or 43.4%, from $2.7 million in the third quarter of fiscal 2023 to $3.9 million in the third quarter of fiscal 2024. The increase was mainly due to increased salaries and benefits, travel expense and rent expense.

Total operating expenses increased 37.9% to $6.6 million for the three months ended September 30, 2024, compared to $4.8 million in the prior year third quarter.

Net loss for the three months ended September 30, 2024, was ($2.5) million, or ($0.06) per basic and diluted share, as compared to net income of $4.0 million, or $0.10 per basic and diluted share, in the three months ended September 30, 2023. Without the one-time charge of approximately $3.6 million due to litigation, net income for the quarter would have been positive.

Nine Months 2024 Financial Results

Revenues increased by $15.7 million, or 20.8%, from $75.5 million for the nine months ended September 30, 2023, to $91.2 million for the nine months ended September 30, 2024. The increase in revenue was primarily due to combined effects of rising demand in the U.S. ATV and UTV market and our modified sales strategy. In 2024, we continued to expand our distribution network with various retailers to increase our products’ market penetration. We strategically focused our efforts on large retail stores in the U.S. (the “big box stores”) that offer their own financing plans, while moving away from retailers that have liberal return policies.

Revenue from sales of UTVs, ATVs and e-bikes increased by $22.2 million, or 33.8%, from $65.8 million for the nine months ended September 30, 2023 to $88.0 million for the nine months ended September 30, 2024. The increase in revenue was primarily attributed to the expansion into more big box stores. This surge is consistent with the increasing ranch/farm-work utilization of UTVs across the 1.89 million farms in the U.S. with an average size of 464 acres and the new customer’s rural lifestyle focus. The increase in sales is also due to a shift in our sales strategy, focusing mostly on in-store sales to this retail chain store customer, which generally involve larger volumes and no returns. In addition, sales to this new customer consist of high-turnover inventory products that are of high quality and have a strong customer reputation. This enhances the efficiency of our capital utilization.

Revenue from sales of Pontoon Boats decreased by $6.6 million, or 67.6%, from $9.7 million for the nine months ended September 30, 2023 to $3.1 million for the nine months ended September 30, 2024. The revenue decrease was primarily due to an industry-wide downturn driven by high interest rates and inflation, which are impacting the consumption of non-essential goods. In addition, the fact that the dealers have experienced high rejection rates at the floorplan financing providers such as Northpoint has directly affected the inventory level the dealers maintain and therefore our sales in this category. This is consistent with the industry-wide trend. The challenging economic environment and economic uncertainty in the U.S. has led to reduced spending on luxury boats directly impacting the sales of luxury boats such as our yacht.

Gross profit increased by $5.1 million, or 21.6%, from $23.8 million for the nine months ended September 30, 2023 to $28.9 million for the nine months ended September 30, 2024. Gross margin was 31.7% for the nine months ended September 30, 2024, compared with 31.5% in the same period last year. Our gross margin for the nine months ended September 30, 2024 remained constant when compared with the same period in 2023.

Cost of revenue on UTVs, ATVs and e-bikes increased by $16.1 million, or 36.9%, from $43.5 million for the nine months ended September 30, 2023, to $59.6 million for the nine months ended September 30, 2024 and gross profit increased by $6.2 million, or 27.9%, from $22.2 million for the nine months ended September 30, 2023, to $28.4 million for the nine months ended September 30, 2024. Gross margin slightly decreased by 1.5%, from 33.8% for the nine months ended September 30, 2023 to 32.3% for the nine months ended September 30, 2024. The increase in the cost of revenue was in line with the increase in sales. The slight decrease in gross profit margin was mainly due to reduced sales prices to clear out slow-moving inventory in the recent quarter.

Cost of revenue on Pontoon Boats decreased by $5.5 million, or 67.5%, from $8.2 million for the nine months ended September 30, 2023, to $2.7 million for the nine months ended September 30, 2024, and gross profit decreased by $1.1 million, or 68.5%, from $1.6 million for the nine months ended September 30, 2023, to $0.5 million for the nine months ended September 30, 2024. Gross margin decreased by 0.4%, from 16.0% for the nine months ended September 30, 2023, to 15.6% for the nine months ended September 30, 2024. Our gross margin for the nine months ended September 30, 2024 remained constant compared to the nine months ended September 30, 2023.

Selling expenses increased by $1.4 million, or 21.3%, from $6.5 million for the nine months ended September 30, 2023, to $7.9 million for the nine months ended September 30, 2024, representing 8.7% and 8.7% of total revenue in both periods. The increase was mainly due to higher shipping and handling fees, partly offset by a reduction in warranty expense of approximately $0.5 million, due to enhanced quality control and customer service.

General and administrative expenses increased by $3.1 million, or 33.8%, from $9.0 million for the nine months ended September 30, 2023, to $12.1 million for the nine months ended September 30, 2024. The increase was mainly due to higher rent expense, salaries and benefit, and insurance expense.

Total operating expenses increased 35.2% to $21.1 million for the nine months ended September 30, 2024, compared to $15.6 million in the prior year period.

Net income for the nine months ended September 30, 2024, was $3.5 million, or $0.09 per basic and diluted share, as compared to net income of $6.6 million, or $0.16 per basic and diluted share, in the nine months ended September 30, 2023.

Cash and cash equivalents totaled $1.7 million at September 30, 2024, as compared to $1.2 million at September 30, 2023.

Net cash used in operating activities was approximately $2.4 million during the nine months ended September 30, 2024, compared to net cash provided by operating activities of approximately $5.8 million during the nine months ended September 30, 2023, representing an increase in the net cash used in operating activities of $8.2 million during the nine months ended September 30, 2024 compared with the same period in 2023. This is consistent with the Company using part of the IPO proceeds as working capital to grow sales.

About Massimo Group

Massimo Group MAMO is a manufacturer and distributor of powersports vehicles and pontoon boats. Founded in 2009, Massimo Motor believes it offers some of the most value packed UTV’s, off-road, and on-road vehicles in the industry. The company’s product lines include a wide selection of farm and ranch tested utility UTVs, recreational ATVs, and Americana style mini-bikes. Massimo Marine manufacturers and sells Pontoon and Tritoon boats with a dedication to innovative design, quality craftsmanship, and great customer service. Massimo is also developing electric versions of UTVs, golf-carts and pontoon boats. The company’s 376,000 square foot factory is in the heart of the Dallas / Fort Worth area of Texas in the city of Garland. For more information, visit massimomotor.com, massimomarine.com and www.massimoelectric.com.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the use of proceeds thereof. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “predict,” “project,” “target,” “potential,” “seek,” “will,” “would,” “could,” “should,” “continue,” “contemplate,” “plan,” and other words and terms of similar meaning. These forward-looking statements include information concerning statements regarding future cash needs, future operations, business plans and future financial results; and any other statements that are not historical facts. No assurance can be given that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Massimo, including those set forth in the “Risk Factors” section of Massimo’s Registration Statement on Form S-1 for the initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. Massimo undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

 

 

 

MASSIMO GROUP AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)






September 30,

2024 

(Unaudited)



December 31,

2023

(Audited)




As of




September 30,

2024 

(Unaudited)



December 31,

2023

(Audited)


ASSETS









CURRENT ASSETS









Cash and cash equivalents


$

1,723,783



$

765,814


Accounts receivable, net



11,557,733




9,566,445


Inventories, net



30,913,746




25,800,912


Advance to suppliers



323,268




1,589,328


Other current assets



567,485




637,509


Total current assets



45,086,015




38,360,008











NON-CURRENT ASSETS









Property and equipment at cost, net



600,034




399,981


Right of use operating lease assets, net



10,125,587




1,478,221


Right of use financing lease assets, net



82,410




113,549


Deferred offering assets






1,457,119


Other non-current assets



49,500





Deferred tax assets



1,109,292




134,601


Total non-current assets



11,966,823




3,583,471


TOTAL ASSETS


$

57,052,838



$

41,943,479











LIABILITIES AND EQUITY









CURRENT LIABILITIES









Short-term loans


$



$

303,583


Accounts payable



9,764,284




12,678,077


Other payable, accrued expenses and other current liabilities



4,007,780




98,097


Accrued return liabilities



163,666




283,276


Accrued warranty liabilities



608,644




619,113


Contract liabilities



1,167,161




1,835,411


Current portion of obligations under operating leases



2,075,541




847,368


Current portion of obligations under financing leases



42,970




41,647


Income tax payable



2,031,571




2,121,083


Loan from a related party



6,416,525





Total current liabilities



26,278,142




18,827,655











NON-CURRENT LIABILITIES









Obligations under operating leases, non-current



8,186,938




630,853


Obligations under financing leases, non-current



44,629




77,024


Loan from a related party






7,920,141


Total non-current liabilities



8,231,567




8,628,018


TOTAL LIABILITIES


$

34,509,709



$

27,455,673











Commitments and Contingencies


















EQUITY









Common shares, $0.001 par value, 100,000,000 shares authorized,
41,329,235 and 40,000,000 issued and outstanding as of September
30, 2024 and December 31, 2023, respectively



41,329




40,000


Preferred shares, $0.01 par value, 5,000,000 preferred shares
authorized, no shares were issued and outstanding as of September
30, 2024 and December 31, 2023, respectively







Subscription receivable






(832,159)


Additional paid-in-capital



5,720,756




1,994,000


Retained earnings



16,781,044




13,285,965


Total equity



22,543,129




14,487,806











TOTAL LIABILITIES AND EQUITY


$

57,052,838



$

41,943,479


 

 

 

MASSIMO GROUP AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHESIVE INCOME

(UNAUDITED)






Three Months Ended



Nine Months Ended




September 30,



September 30,




2024



2023



2024



2023















Revenues


$

25,602,310



$

29,907,697



$

91,156,640



$

75,483,811


Cost of revenues



18,649,995




19,850,258




62,253,681




51,706,682


Gross profit



6,952,315




10,057,439




28,902,959




23,777,129



















Operating expenses:

















Selling expense



2,628,915




2,104,505




7,936,761




6,541,244


General and administrative



3,895,232




2,716,733




12,096,874




9,038,488


Impairment loss on supplier deposit



29,883







772,780





Research and development



94,771







257,021





Total operating expenses



6,648,801




4,821,238




21,063,436




15,579,732



















Income from operations



303,514




5,236,201




7,839,523




8,197,397



















Other income (expense):

















Other income, net



210,701




41,133




590,538




113,001


Loss on litigation



(3,573,651)







(3,573,651)





Interest expense



(64,462)




(213,901)




(268,803)




(494,011)


Total other (expense) income, net



(3,427,412)




(172,768)




(3,251,916)




(381,010)



















(Loss) income before income taxes



(3,123,898)




5,063,433




4,587,607




7,816,387



















(Recovery of ) provision for income
taxes



(621,665)




1,106,046




1,092,528




1,236,551



















Net (loss) income and comprehensive
(loss) income


$

(2,502,233)



$

3,957,387



$

3,495,079



$

6,579,836



















(Loss) Earnings per Share – basic


$

(0.06)



$

0.10



$

0.09



$

0.16


Weighted average shares outstanding –
basic *



41,325,388




40,000,000




40,863,370




40,000,000


(Loss) Earnings per Share –diluted


$

(0.06)



$

0.10



$

0.09



$

0.16


Weighted average shares outstanding –
diluted*



41,325,388




40,000,000




41,005,556




40,000,000




*     Retroactively restated for effect of reorganization


 

 

 

MASSIMO GROUP AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)




Nine Months Ended September 30,




2024



2023









Cash flows from operating activities:









Net income


$

3,495,079



$

6,579,836


Adjustments to reconcile net income to net cash provided by
operating activities:









Depreciation



98,111




109,765


Non-cash operating lease expense



1,342,402




793,577


Accretion of finance lease liabilities



3,672




5,610


Amortization of finance lease right-of-use assets



31,139




31,733


Written-off of account receivables






420,967


Provision of (Reversal of) allowance for excepted credit loss, net



223,051




(118,144)


Gain on disposal of fixed asset



(36,001)





Impairment loss of asset



772,780





Loss on litigation



3,573,651





RSU compensation



426,666





Share-based compensation for services



131,699





Deferred tax assets



(974,691)




(65,158)


Changes in operating assets and liabilities:









Accounts receivable



(2,214,339)




(1,631,919)


Inventories



(5,002,834)




(36,157)


Reversal of inventory impairment



(110,000)





Advance to suppliers



493,280




(130,580)


Other current assets



20,524




(818,397)


Related party payable






398,700


Accounts payables



(2,913,793)




(373,314)


Other payable, accrued expense and other current liabilities



336,032




(154,530)


Tax payable



(89,512)




1,237,709


Accrued warranty liabilities



(10,469)




205,868


Accrued return liabilities



(119,610)




(341,317)


Contract liabilities



(668,250)




457,936


Lease liabilities – operating lease



(1,205,510)




(793,577)


Net cash (used in) provided by operating activities



(2,396,923)




5,778,608











Cash flows from investing activities:









Proceed from sales of property and equipment



162,001





Acquisition of property and equipment



(424,164)




(68,871)


Net cash used in investing activities



(262,163)




(68,871)











Cash flows from financing activities:









Repayment of other loans



(303,583)




(1,600,000)


Repayment of finance lease liabilities



(34,744)




(35,469)


Proceed from common share issuances



80,000





Deferred offering costs






(263,162)


Proceeds from initial public offering, net of share issuance costs



4,458,667





Repayment of loan from a related party



(1,503,616)




(3,982,876)


Proceeds from subscription deposits



920,331




381,841


Net cash provided by (used in) financing activities



3,617,055




(5,499,666)











Net increase in cash and cash equivalents



957,969




210,071


Cash and cash equivalents, beginning of the period



765,814




947,971


Cash and cash equivalents, end of the period


$

1,723,783



$

1,158,042











SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION:









Cash paid for interest


$

244,173



$

494,011


Cash paid for income taxes


$

2,156,731



$

64,000











NON-CASH ACTIVITIES









Right of use assets obtained in exchange for operating lease
obligations


$

9,758,345



$

1,113,140


Right of use assets obtained in exchange for finance lease


$



$

60,805


 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/massimo-group-reports-third-quarter-2024-financial-results-302306872.html

SOURCE Massimo Group

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It

On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Altria Group, Inc. MO is “undervalued,” but he is not going to recommend tobacco stocks.

On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. It beat the street view of $1.35. Quarterly sales of $5.334 billion (+1.3%) beat the analyst consensus estimate of $5.326 billion.

Cramer recommended selling Super Micro Computer, Inc. SMCI.

Super Micro Computer filed a FormNT 10-Q with the Securities and Exchange Commission, indicating that it’s unable to file its 2025 fiscal-year first-quarter earnings on time.

When asked about The Boeing Company BA, he said, “I prefer not to be in a stock that is going to lose a lot of money for a long time.”

According to Reuters, the company reportedly begins issuing layoff notices to employees affected by a major restructuring plan. The plan, which aims to reduce Boeing’s global workforce by 17,000 jobs—approximately 10% of its total—comes as the heavily indebted aerospace giant seeks to cut costs.

Becton, Dickinson and Company BDX has “broken down severely,” Cramer said. “If Robert F. Kennedy Jr. is going to be the head of HHS, then it’s going to hurt a lot of vaccines, it could hurt a lot of their business.”

On Nov. 7, the company posted better-than-expected results for its fourth quarter.

“They have a lot of phase one stuff, and phase one is might early. Too early for me to bet on,” Cramer said when asked about IDEAYA Biosciences, Inc. IDYA.

On Nov. 4, IDEAYA Biosciences reported a quarterly loss of 60 cents per share, compared to consensus estimates of a loss of 64 cents per share.

“I just don’t know what is wrong,” Cramer said about AstraZeneca PLC AZN. “My god is this thing going lower.”

On Nov. 12, AstraZeneca reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.

Price Action:

  • Altria shares rose 0.3% to settle at $55.39 on Thursday.
  • Super Micro Computer shares dipped 11.4% to close at $18.01.
  • Boeing shares fell 1.3% to settle at $138.14 during the session.
  • Becton Dickinson shares fell 1.8% to close at $227.17 on Thursday.
  • IDEAYA Biosciences shares fell 3.4% to settle at $29.47 during the session.
  • AstraZeneca shares fell 0.4% to close at $65.04 on Thursday.

Read Next:

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

Tesla CEO And DOGE Co-Lead Elon Musk Says 'Excess Government Spending' Causes Inflation: Here's What Experts Say

As U.S. headline and core consumer price inflation increased in October and GDP growth remained resilient in Q3, billionaire Elon Musk has presented a hot take on how “excess” government spending is a major cause of inflation.

Tesla Inc. and SpaceX CEO, Musk – who has been named co-lead of DOGE or Department of Government Efficiency along with Republican politician Vivek Ramaswamy – has yet again signaled his vision going into this new role which is also meant to “restructure federal agencies and reduce government spending.”

Also read: Trump’s DOGE With Musk At The Helm ‘Riddled With Conflicts Of Interest’ Says, Clinton-Era Official Robert Reich

Balance Between Income And Expenditure

While government spending and its revenue streams determine how the economy will look, it also depends on other large fiscal and monetary decisions. An expansionary fiscal policy reduces the budget surplus or increases the budget deficit.

In general, decreased taxes and increased government spending, both increase a budget deficit, overall demand, economic growth, and employment. All the Keynesian economists, who follow the work of British economist John Maynard Keynes, believe that fiscal policy, through its effect on aggregate demand, can strongly impact economic growth.

To simplify this, if an individual spends more than they earn, they will have to borrow money to meet their needs. A steady supply from lenders and low interest rates will just increase the amount of debt held by the individuals. This is why in the current context, the Treasury yields have risen, pricing in the inflation expectations. Thus, the balance between income and expenditure becomes imperative. However, in the larger context, a country usually adjusts its budget deficit or surplus to maintain balance and stability.

Thus, Musk’s claim on higher government spending, in contrast to, less earnings via taxes, tariffs, or other channels, causes inflation to rise.

Replying to Musk’s tweet, Steve Burns, trader and founder of NewTraderU.com, shared a rare video of the Nobel Prize-winning economist Milton Friedman, where he talks about what causes inflation according to his theory.

However, monetarists believe that fiscal stimulus’s effect is only temporary and that monetary policy should increase or decrease inflationary pressures over time instead of influencing aggregate demand to counter-cyclical movements in the economy.

See Also: Trump Appoints Elon Musk And Vivek Ramaswamy To Lead ‘DOGE,’ Aiming to Slash Bureaucracy And $6.5 Trillion Federal Spending

The Catch 22

According to Musk’s ideas, increasing the government’s revenue stream and decreasing spending can help control inflation.

However, consumers don’t prefer higher taxes which most likely prompts DOGE co-head Musk to decrease federal spending via the contribution of their findings by the proposed task force.

Guy Berger, the director of economic research at the Burning Glass Institute, states how higher taxes affect consumers and how the monetary policy has its own limitations as they cannot target rates below “zero” to control inflation.

Additionally, President-elect Donald Trump has also spoken about imposing higher tariffs and cutting tax rates, both of which could result in higher inflation.

A tariff placed on imported goods increases their prices domestically while decreasing the quantity imported. Domestic producers gain, foreign exporters lose, and the domestic government only gains by the amount of the tariff revenues.

While the proposed policies have a conflicting view as compared to what is necessary to control inflation, a strategic and well-planned fiscal and monetary policy is important to control inflation while maintaining economic growth. Berger adds that “one technical solution here is less reliance on ad hoc stimulus packages, and more on rule-based automatic stabilizers.”

Even though Musk believes that cutting “wasteful government spending” can help curtail inflation, the larger picture in line with Trump’s promised policies doesn’t seem simple.

To sum it up, “When the economy is sick, give it the medicine it needs, when it needs it, at doses calibrated to the intensity of the illness,” adds Berger.

Impact On Treasury Yields

In the current context as the inflation fears continue to linger, U.S. Treasury yields have also spiked. This means that debt is cheaper, giving away more purchasing power to debtholders, thus stoking inflation.

Considering the October CPI data, Federal Reserve Chair Jerome Powell, using monetary policy as a tool, has pared back the interest rate cut expectations. “The economy is not sending any signals that we need to be in a hurry to lower rate,” Powell said on Thursday in Dallas.

The two-year yields ended Thursday at 4.32%, whereas the ten-year yields jumped to 4.42%. Fiscally, if the government borrows more from the public after cutting taxes the longer end of the yield curve is also bound to rise, signaling inflation fears.

Read Next:

Image via Flickr

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Frozen Meat Market Size Anticipated to Cross USD 31.7 billion, registering a CAGR of 3.6% by 2031: Transparency Market Research, Inc.

Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 15, 2024 (GLOBE NEWSWIRE) — The global frozen meat market (냉동 고기 시장) is estimated to flourish at a CAGR of 3.6% from 2023 to 2031. Transparency Market Research projects that the overall sales revenue for frozen meat is estimated to reach US$ 31.7 billion by the end of 2031. Growing awareness of health-conscious consumer choices is driving the demand for frozen meat products with minimal additives, preservatives, and healthier processing methods.

The rise of plant-based frozen meat substitutes is influencing the market, reflecting shifting dietary preferences and a surge in vegetarian and flexitarian lifestyles. Manufacturers are focusing on innovative frozen meat product formulations, incorporating diverse flavors, ethnic cuisines, and unique recipes to meet evolving consumer tastes and preferences.

Environmental consciousness is driving the adoption of sustainable and eco-friendly packaging for frozen meat products, aligning with consumer demands for responsible consumption. Increasing emphasis on locally sourced and ethically produced frozen meat options, responding to consumers’ interest in supporting regional economies and sustainable agricultural practices.

Get Access to Sample PDF Research Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=38306


Frozen Meat Market: Competitive Landscape

The frozen meat market is marked by intense competition, with key players driving innovation and quality. Industry leaders such as JBS S.A., Tyson Foods Inc., and BRF S.A. dominate, leveraging extensive global networks and diverse product portfolios.

These giants compete with regional players like Marfrig Global Foods and NH Foods Ltd., fostering a dynamic market environment. Strategic acquisitions, product diversification, and adherence to stringent quality standards characterize the competitive landscape.

As consumers seek convenient, high-quality frozen meat products, the market’s competitive dynamics continue to evolve, with companies aiming for market share through differentiation and responsiveness to changing consumer preferences. Some prominent manufacturers are as follows:

  • Cargill Incorporated
  • Kerry Group Plc
  • Marfrig Group
  • BRF S.A.
  • Associated British Foods Plc.
  • Tyson Foods
  • Pilgrim’s Pride Corporation Inc.
  • Verde Farms LLC
  • Arcadian Organic & Natural Meat Co.
  • JBS S.A.
  • VH Group
  • AJC International Inc.
  • Keystone Foods
  • Mindful Meats
  • Pitrman Family Farms

Product Portfolio

  • JBS S.A. is a global leader in the food industry, offering a diverse product portfolio. Renowned for high-quality meat products, JBS provides a range of beef, poultry, and pork solutions, meeting the demands of consumers worldwide with a commitment to sustainability and excellence.
  • VH Group stands as a prominent player in the poultry industry, specializing in the production of premium-quality eggs and poultry products. With a focus on innovation and sustainability, VH Group ensures a consistent supply of nutritious and responsibly sourced products.
  • AJC International Inc. excels in global food trade, providing a comprehensive product portfolio. Specializing in poultry, pork, beef, and seafood, AJC International delivers quality food products worldwide, emphasizing reliability, sustainability, and customer satisfaction.

Key Findings of the Market Report

  • Chicken leads the frozen meat market, driven by its versatility, widespread popularity, and consumer preference for convenient, lean protein options.
  • Retail/household stands as the leading end-use segment in the frozen meat market, driven by consumer demand for convenient and accessible food options.
  • Hypermarkets/supermarkets lead the frozen meat market distribution channel, offering a wide variety of frozen meat products to diverse consumer segments. 

Frozen Meat Market Growth Drivers & Trends

  • Busy lifestyles drive increased consumption of frozen meat products.
  • Urbanization contributes to the growth of the frozen meat market, catering to on-the-go consumers.
  • Diverse culinary preferences and globalization trends fuel demand for a variety of frozen meat products.
  • Growing affluence in emerging economies leads to greater affordability and accessibility of frozen meat options.
  • Innovations in cold chain logistics ensure the quality and safety of frozen meat products, boosting market expansion.

Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=38306

Global Frozen Meat Market: Regional Profile

  • North America boasts a mature market driven by the widespread adoption of frozen meat products, reflecting busy lifestyles and the demand for convenient yet high-quality food options.
  • Europe emphasizes sustainability and diverse culinary preferences, contributing to a dynamic market.
  • Asia Pacific shows substantial growth potential, fueled by rising disposable incomes, urbanization, and changing dietary habits. With a surge in demand for frozen meat products in countries like China and India, the region is a focal point for market expansion.

Frozen Meat Market: Key Segments

By Type

By End Use

  • Food Processing Industry
  • Foodservice
  • Retail/Household

By Distribution Channel

  • Business to Business
  • Business to Consumer
  • Hypermarkets/Supermarkets
  • Convenience Stores
  • Specialty Stores
  • Online Retail

By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Buy this Premium Research Report:

https://www.transparencymarketresearch.com/checkout.php?rep_id=38306&ltype=S

Explore More Trending Report by Transparency Market Research:

Pet Food Market (ペットフード市場) Revenue to Cross USD 168.3 billion by 2029, Booming at a CAGR of 6%: TMR Report

Chelated Minerals Market (سوق المعادن المخلبة) to Surpass of US$ 7.38 Bn by 2031, TMR Study

About Transparency Market Research 

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. 

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com    
Email: sales@transparencymarketresearch.com
Follow Us: LinkedInTwitterBlog | YouTube


Primary Logo

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus

NAPLES, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) — via IBN – HealthLynked Corp. HLYK, a leader in healthcare networking and technology innovation, today announced financial results for the three- and nine-months ending Sept. 30, 2024. With a renewed commitment to profitable growth, HealthLynked has restructured its clinical operations, reduced its third-party debt obligations, reduced physical plant cost and shifted focus toward its core software solutions, positioning the company for enhanced operational efficiency and scalability in the future.

Financial Highlights

Revenue: HealthLynked reported revenue of $0.59 million in the third quarter of 2024, reflecting a 56% decrease year-over-year from $1.33 million in Q3 2023 and a 26% sequential decline from $0.80 million in Q2 2024. For the first nine months of 2024, revenue totaled $2.39 million, a 12% drop from the preceding nine-month period (October 2023 to June 2024) and a 50% decrease from $4.79 million in the first nine months of 2023. This decline is primarily due to expected clinical revenue disruption resulting from our restructuring efforts related to onboarding of new clinical staffing, consolidating clinical locations and other right-sizing efforts.

Expense Reductions: HealthLynked reduced practice operating expenses by $0.50 million, or 39%, in Q3 2024 to $0.80 million, compared to $1.30 million in Q3 2023. Year-to-date, expenses decreased by 38%, underscoring the company’s continued focus on efficiency. Overall, total operating expenses fell by 10% in Q3 2024 compared to Q3 2023 and by 19% in the first nine months of 2024 compared to the same period in 2023.

Loss from Operations: The loss from operations for Q3 2024 was increased by $0.49 million. From $1.18 million, to $1.67 million loss in Q3 2023. Year-to-date, the loss from operations was $3.93 million, representing a 29% increase over the $3.04 million loss in the same period of 2023.

Net Income/Loss: HealthLynked reported a net loss of $1.97 million in Q3 2024, compared to a net loss of $0.17 million in Q3 2023. This difference was primarily attributable to a $1.08 million gain in 2023 related to the sale of ACO Health Partners. For the first nine months of 2024, the net loss was $4.90 million, contrasting with a net income of $0.27 million in the same period of 2023, primarily due to $3.76 million gains related to the ACO Health Partners sale recorded in 2023.

Strategic Outlook

HealthLynked remains committed to expanding its footprint through strategic partnerships and a growing user base. The company is shifting its focus from traditional clinical operations to app-based services, aiming to increase both user acquisition and revenue through innovative digital solutions. By leveraging its patient-centric network, HealthLynked anticipates significant growth in its membership base, enhancing healthcare accessibility for patients and providers alike.

HealthLynked’s software platform’s cost is significantly lower than the variable costs associated with operating clinical services. This shift allows HealthLynked to minimize the fluctuations in costs and revenue that typically accompany clinic operations, resulting in a leaner, more efficient business model.

CEO Contribution and Financial Support

Dr. Michael Dent, CEO of HealthLynked, has played a crucial role in providing the necessary financial support for the company’s operations during this period of transition, with $2.7 million in debt funded so far in 2024. His commitment has enabled HealthLynked to navigate this restructuring phase successfully, setting a foundation for future growth as the company benefits from reduced third-party debt service and an optimized cost structure.

Executive Commentary

Dr. Michael Dent, CEO of HealthLynked, stated, “Our restructuring efforts in our clinical operations are designed to maximize profitability and support our transition toward core technology solutions. With telemedicine services just now available in all 50 states and our paid concierge services gaining traction, HealthLynked is well-positioned to drive revenues by focusing on the value of our patient-centric software platform. This shift allows us to better serve patients and providers across the nation, reducing operational overhead while expanding our reach and impact in healthcare.”

About HealthLynked

HealthLynked Corp. is dedicated to improving global community health. Our mission is to transform healthcare into a system marked by enhanced efficiency and improved care for all, leveraging cutting-edge technology and connectivity that places patients at the heart of their healthcare journey. The HealthLynked Network is a sophisticated cloud-based platform designed to facilitate the seamless exchange of medical information among patients and healthcare providers. By centralizing and securing medical data, the HealthLynked Network empowers patient members to manage their healthcare with unparalleled ease and efficiency, while offering providers an environment where they can gain valuable insights into practice operations, enhance patient compliance, and optimize scheduling.

For more information about HealthLynked Corp., including details on how to become part of our growing community, please visit our website at www.healthlynked.com. Connect with us on social media through Twitter, Facebook, Instagram, and LinkedIn to stay updated on our latest innovations and services. Download the HealthLynked App for Apple or Android.

Forward-Looking Statements & Risk Factors

Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results, including as a result of any acquisitions, performance, or achievements, may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would,” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by our management and us, are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information, or future events, changes in assumptions, or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Certain risks and uncertainties applicable to our operations and us are described in the “Risk Factors” section of our most recent Annual Report on Form 10-K and in other filings we have made with the U.S. Securities and Exchange Commission. These reports are publicly available at www.sec.gov.

Contact Information:

Mike Paisan

HealthLynked Corp.
1265 Creekside Pkwy, Suite 301
Naples, Florida 34108
Phone: 1-800-928-7144
Email: IR@healthlynked.com

 
HealthLynked Corp.
Selected Consolidated Financial Data
Three and Nine Months Ended September 30, 2024 and 2023
 
  Three Months Ended September 30,   Nine Months Ended September 30,
    2024       2023       2024       2023  
Statement of Operations Data:                      
Total revenue $ 590,124     $ 1,332,515     $ 2,389,434     $ 4,791,165  
Loss from operations $ (1,671,347)     $ (1,184,843)     $ (3,928,874)     $ (3,039,569)  
Loss from continuing operations $ (1,973,119)     $ (161,370)     $ (4,901,273)     $ (2,328,218)  
Gain (loss) from discontinued operations $     $ (13,554)     $     $ 2,601,774  
Net income (loss) $ (1,973,119)     $ (174,924)     $ (4,901,273)     $ 273,556  
                       
Earnings (loss) per share data, basic and diluted:                      
Loss from continuing operations $ (0.01)     $ (0.00)     $ (0.02)     $ (0.01)  
Gain (loss) on discontinued operations $ 0.00     $ (0.00)     $ 0.00     $ 0.01  
Net income (loss) $ (0.01)     $ (0.00)     $ (0.02)     $ 0.00  
Weighted average number of common shares   281,947,151       265,519,460       281,428,579       260,853,370  
                       
                       
  September 30,   December 31,            
Balance Sheet Data: 2024     2023              
Total Assets $ 2,758,158     $ 4,280,140              
Total Liabilities $ 4,691,077     $ 3,475,410              
Total Shareholders’ Equity $ (1,932,919 )   $ 804,730              
 

Wire Service Contact:
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com


Primary Logo

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Cardiovascular Devices Market Overview: Growth Drivers and Competitive Landscape | Exactitude Consultancy

Luton, Bedfordshire, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) — The global cardiac device market is experiencing tremendous growth. This is driven by the increasing prevalence of chronic heart disease. This increase in heart conditions is driving the use of high-tech devices for diagnostic and surgical purposes. In addition, the price drop of critical cardiac medical equipment such as coronary stents is decreasing. It is helping to increase market expansion. Particularly in emerging markets like India, Harvard’s T.H. Chan School of Public Health found that the number of heart procedures in Maharashtra increased 43% as the price of coronary stents dropped. It emphasizes the positive impact of affordable medical devices on patients’ treatment choices.

Access PDF Sample Report (Including Graphs, Charts & Figures) @

https://exactitudeconsultancy.com/reports/24647/cardiovascular-devices-market/#request-a-sample

This growth trend will continue. with key market players increasing their R&D efforts to develop innovative products designed to improve outcomes for cardiovascular patients. The increasing incidence of cardiovascular disease across the world is also fueling the expansion of this market. As a result, the cardiology devices market is poised for strong growth throughout the forecast period. Although the spread of COVID-19 will have a negative impact on the market. This is especially true because elective heart surgery procedures have been postponed and hospital admissions have decreased. But the market is continuing to recover. The pandemic has delayed non-urgent procedures, such as percutaneous coronary intervention (PCI) for stable ischemic heart disease. This is because health care resources have been redirected to managing COVID-19. But demand for cardiac equipment is increasing. Innovative products…from the beginning have helped The market returns to its pre-epidemic growth trajectory.

  • Technological Innovation in Cardiology Devices: Major players in the industry continue to focus on developing cutting-edge diagnostic and therapeutic solutions, such as AI-powered diagnostic tools and advanced stent technologies, to enhance patient outcomes and broaden market adoption.
  • Regional Expansion: The demand for cardiology devices is expected to rise significantly in emerging markets, particularly in regions like Asia-Pacific and Latin America, as healthcare infrastructure improves and access to advanced medical technologies increases.
  • Government Initiatives: Governments worldwide are increasingly prioritizing healthcare reforms, including the expansion of cardiology services, which is expected to further drive demand for heart disease-related medical devices.

High Demand for Advanced Cardiovascular Devices Drives Market Growth

The growing demand for advanced cardiovascular devices is propelled by an increasing number of patients suffering from chronic heart diseases, many of whom require state-of-the-art diagnostic and therapeutic solutions. This is particularly true for coronary stents and other devices with enhanced safety features. Patients now seek devices that not only provide effective treatment but also minimize the risk of complications, such as infections often associated with bare-metal stents.

Technological advancements have also spurred a demand for devices with remote cardiac monitoring capabilities. These features provide patients with accurate, real-time insights into their heart health, improving overall treatment efficacy and patient convenience. As a result, leading manufacturers in the cardiovascular devices market are prioritizing the development of innovative, feature-rich products. For example, in November 2021, Medtronic launched the Arctic Front Cardiac Cryoablation Catheter System, the first cryoballoon catheter to receive CDSCO approval, designed for treating atrial fibrillation. Similarly, in February 2021, Remo Care Solutions introduced an AI-powered remote cardiac monitoring device, Remo.Cardia, which analyzes patients’ vitals in real-time, offering effective monitoring for individuals with cardiovascular conditions.

The growing patient pool, paired with the increasing demand for advanced features, is expected to significantly drive the growth of the cardiovascular devices market in the coming years.

  1. Technological Advancements and Patient-Centered Features: The rising preference for devices that integrate features like AI, wireless connectivity, and remote monitoring is making these tools indispensable for both healthcare professionals and patients. These devices not only provide real-time data but also enable more tailored and effective treatment plans, which is especially important for individuals in need of continuous monitoring.
  2. Emerging Markets: The rise of emerging markets, where a greater focus on affordability and accessibility of advanced cardiovascular devices is occurring, is also a significant driver. Increased awareness and healthcare infrastructure improvements in countries such as India, Brazil, and China are contributing to the demand for cost-effective yet advanced cardiovascular technologies.
  3. Market Recovery Post-COVID-19: While the pandemic temporarily disrupted elective cardiovascular procedures, there is now a rebound in the demand for cardiovascular devices as health systems resume normal operations. The resurgence in heart disease diagnoses and treatments is fueling further growth in this sector.

Increase in Cardiovascular Diseases Prevalence to Drive Global Market Growth

The global cardiovascular devices market is poised for significant growth, largely driven by the rising prevalence of heart diseases. Cardiovascular diseases (CVDs) are among the most costly in terms of healthcare services, and conditions such as coronary artery disease (CAD) and heart failure are becoming increasingly prevalent. Coronary stents, crucial devices used in treating life-threatening conditions such as heart attacks, atrial fibrillation, and blocked arteries, are in high demand as they offer vital treatment for patients with these conditions.

Data from the Centers for Disease Control and Prevention (CDC) highlighted that in 2022, approximately 4.9% of adults in the U.S. were diagnosed with coronary heart disease, and CVDs remain the leading cause of death in the country, accounting for 695,547 deaths in the same year. Globally, the World Health Organization (WHO) estimates that heart diseases are responsible for approximately 17.9 million deaths annually. These alarming statistics emphasize the increasing need for innovative and advanced cardiovascular devices.

Further driving market expansion, the surge in device approvals by regulatory authorities is expected to fuel market growth. Additionally, various public initiatives aimed at expanding access to cardiovascular devices in developing regions are expected to enhance market prospects, particularly in underserved areas.

  1. Regulatory Approvals and Innovation: The acceleration in approvals for new devices by regulatory bodies like the FDA and European Medicines Agency (EMA) has provided a significant boost to the market. Companies are focusing on research and development to introduce innovative technologies, improving treatment options for patients worldwide.
  2. Rising Awareness in Developing Markets: Countries in Asia, Africa, and Latin America are seeing an increase in healthcare awareness and infrastructure development, which is contributing to the rising demand for cardiovascular devices. This presents substantial opportunities for manufacturers targeting emerging markets.
  3. Aging Population: As the global population continues to age, the incidence of chronic heart conditions is expected to rise. This demographic shift further underscores the growing need for cardiovascular devices that can address a wide range of heart diseases.

Report Link Click Here: https://exactitudeconsultancy.com/reports/24647/cardiovascular-devices-market/

Increasing Availability of Efficient Devices to Propel Market Growth

The global cardiovascular devices market is witnessing significant growth, driven by the increasing prevalence of heart diseases and the expanding availability of advanced and cost-effective devices. As healthcare systems in emerging markets such as India, China, and Mexico continue to develop, the demand for these life-saving technologies has surged. With numerous initiatives aimed at improving access to affordable cardiovascular devices in these regions, market growth is set to accelerate in the coming years.

For example, in January 2023, UltraLinQ Healthcare Solutions introduced a new cardiac monitoring product at the Arab Health 2023. This end-to-end system allows specialist clinics and hospitals to offer Holter services remotely, enhancing patient access to care, even in the comfort of their homes. Such innovations are helping bridge healthcare gaps in emerging economies, further driving the adoption of cardiovascular devices.

Increasing Barriers in R&D Activities Could Restrict Market Growth

Despite these positive developments, the cardiovascular devices market faces challenges in terms of research and development (R&D) efforts. The high costs associated with the advancement of innovative devices, compounded by ineffective reimbursement models, have created barriers to progress. For example, countries that impose price caps on essential life-saving devices, such as coronary stents, discourage manufacturers from investing in new product developments. This can slow innovation and the introduction of advanced devices into the market.

Additionally, stringent regulatory policies are also restricting market growth. Devices that do not meet regulatory guidelines cannot be commercialized, resulting in financial losses for manufacturers. Furthermore, product recalls have become more frequent in recent years, tarnishing the reputation of manufacturers. For instance, in 2023, the U.S. FDA announced that Abbott recalled its NC Traveler RX Coronary Dilatation Catheters due to issues with balloon deflation. These challenges underscore the hurdles manufacturers must navigate to ensure the continued growth and innovation of the cardiovascular devices market.

North America to Maintain Dominance in the Cardiovascular Devices Market

North America continues to dominate the global cardiovascular devices market, with the U.S. accounting for a significant share in 2023. This is driven by a combination of factors including the prevalence of cardiovascular diseases, increased healthcare expenditure, and robust access to advanced medical infrastructure. According to the American Heart Association, cardiovascular diseases were responsible for around 18.6 million deaths in the U.S. in 2019, highlighting the significant burden of these diseases. The growing adoption of innovative medical technologies, alongside favorable reimbursement policies and a strong healthcare infrastructure, has led to an increased demand for cardiovascular diagnostic devices and surgical interventions across the region.

Asia Pacific: The Fastest-Growing Market for Cardiovascular Devices

The Asia Pacific (APAC) region is expected to exhibit the fastest growth in the cardiovascular devices market during the forecast period. This growth is driven by factors such as a large population base, rising incidence of cardiovascular diseases, increasing healthcare expenditure, and investments in healthcare infrastructure. According to the World Health Organization, approximately 75% of deaths from cardiovascular diseases occur in low- and middle-income countries, underscoring the region’s vulnerability. The increasing accessibility to healthcare services, alongside the rising affordability of medical technologies, is fueling the adoption of cardiovascular devices in these areas. Moreover, the rapidly expanding geriatric population, which is expected to constitute 80% of the global elderly population by 2050, will further drive the demand for cardiovascular devices in the APAC region.

Key Drivers of Cardiovascular Devices Market Growth

The global cardiovascular devices market is experiencing significant growth due to several key factors, most notably the increasing prevalence of chronic cardiovascular diseases worldwide. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, accounting for an estimated 17.9 million deaths each year. Key contributors to this rise include unhealthy diets high in salt, increased tobacco use, alcohol consumption, and the growing incidence of obesity and physical inactivity, all of which heighten the risk of cardiovascular conditions.

The demand for early diagnosis is a major factor in driving the market, as early detection of cardiovascular diseases can significantly improve treatment outcomes. In addition, the aging population is contributing to the rise in cardiovascular diseases, as older individuals are more susceptible. The United Nations projects that by 2050, the global geriatric population will reach approximately 2 billion, further increasing the demand for cardiovascular care.

The market is also buoyed by technological advancements, particularly in product innovations. For example, in February 2021, Remo Care Solutions introduced an AI-based remote monitoring device designed to analyze real-time cardiovascular conditions of patients. This integration of artificial intelligence (AI) into cardiovascular devices is enhancing patient care services and helping to reduce mortality rates. Additionally, the rising investments by leading market players in research, development, and clinical trials are expected to open new avenues for growth in the coming years, further accelerating the demand for these critical devices.

Cardiovascular Devices Market Key Players:

  • B. Braun Melsungen AG (Melsungen, Germany)
  • Medtronic (Dublin, Ireland)
  • Abbott (Abbott Park, U.S.)
  • Boston Scientific Corporation (Marlborough, U.S.)
  • Edwards Lifesciences Corporation (Irvine, U.S.)
  • Johnson & Johnson Services, Inc. (New Brunswick, U.S.)
  • GENERAL ELECTRIC COMPANY (GE Healthcare) (Chicago, U.S.)
  • LivaNova PLC (London, U.K.)
  • Siemens Healthcare GmbH (Erlangen, Germany)
  • Terumo Cardiovascular Systems Corporation (Tokyo, Japan)
  • Medtronic
  • LivaNova Plc
  • Edwards Lifesciences Corporation
  • GE Healthcare
  • Siemens Healthcare GmbH

Key Developments

  • In 2023, a new ablation technology, pulsed field ablation (PFA), showed promise as a safer and faster alternative to traditional thermal ablation for treating atrial fibrillation (AFib). This technique uses electrical fields to target heart muscle cells without damaging surrounding tissues, offering a potentially more effective treatment for AFib patients​.
  • Recent studies have confirmed that endovascular thrombectomy, a minimally invasive procedure to remove blood clots from the brain, benefits even patients with large, severe strokes. This development could improve outcomes for patients who previously had limited treatment options​.
  • In recent trials, advanced imaging technologies have improved the placement of stents in patients with complex coronary lesions. These new techniques help doctors achieve better outcomes for patients with challenging heart conditions, including those with diabetes​.
  • Zilebesiran, a new drug targeting blood pressure regulation, showed positive results in clinical trials by offering long-lasting blood pressure reductions with a single injection. This medication could potentially become a significant advancement in treating hypertension and related cardiovascular conditions​.
  • In February 2021, Remo Care Solutions introduced an AI-based remote monitoring device for cardiac patients. This device analyzes cardiovascular conditions in real time, improving management and potentially reducing hospital visits​.

Segments Covered in the Report

By Device Type

  • Diagnostic & Monitoring
    • ECG
    • Holter Monitors
    • Event Monitors
    • Implantable Loop Recorders
    • Echocardiogram
    • Pet Scan
    • MRI
    • Cardiac CT
    • Doppler Fetal Monitors
  • Therapeutic & Surgical Devices
    • Pacemakers
    • Stents
    • Catheters and accessories
    • Guidewires
    • Cannulae
    • Electrosurgical Procedures
    • Valves
    • Occlusion Devices
    • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Application

  • Cardiac Arrhythmia
  • Coronary Artery Disease
  • Heart Failure
  • Others

By Geography

  • North America
  • Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • MEA
  • Latin America
  • Rest of the World

Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/24647/cardiovascular-devices-market/#request-a-sample

Related Reports:

Optical Imaging Market

https://exactitudeconsultancy.com/reports/2375/optical-imaging-market/

The global optical imaging market is expected to grow at more than 15.1% CAGR from 2019 to 2028. It is expected to reach above USD 4.25 billion by 2028 from a little above USD 1.11 billion in 2019.

Denture Market

https://exactitudeconsultancy.com/reports/5020/denture-market/

The global denture market is expected to grow at 6% CAGR from 2022 to 2029. It is expected to reach above USD 3.48 billion by 2029 from USD 2.15 billion in 2020.

Electronic Drug Delivery Systems Market

https://exactitudeconsultancy.com/reports/1262/electronic-drug-delivery-systems-market/

The Global Electronic Drug Delivery Systems Market is expected to grow at 8.1% CAGR from 2019 to 2028. It is expected to reach above USD 14.36 million by 2028 from USD 7.50 million in 2019.

Medical Adhesives Market

https://exactitudeconsultancy.com/reports/3134/medical-adhesives-market/

The medical adhesive market is projected to grow from USD 8.14 billion in 2020 to USD 15.60 billion by 2029, at a CAGR of 7.5% between 2022 and 2029.

Cryogenic Equipment Market

https://exactitudeconsultancy.com/reports/5442/cryogenic-equipment-market/

The global cryogenic equipment market is expected to grow at more than 7.2% CAGR from 2022 to 2029. It is expected to reach above USD 41.5 billion by 2029 from USD 22.19 billion in 2020.

Peripheral Vascular Devices Market

https://exactitudeconsultancy.com/reports/5615/peripheral-vascular-devices-market/

The global peripheral vascular devices market is expected to grow at 6% CAGR from 2022 to 2029. It is expected to reach above USD 17.74 billion by 2029 from USD 10.5 billion in 2020.

Transcatheter Aortic Valve Replacement (TAVR) Market

https://exactitudeconsultancy.com/reports/3811/transcatheter-aortic-valve-replacement-tavr-market/

The global transcatheter aortic valve replacement (TAVR) market is expected to grow at 22% CAGR from 2022 to 2029. It is expected to reach above USD 26 billion by 2029 from USD 4.34 billion in 2020.

Infusion Pump Market

https://exactitudeconsultancy.com/reports/1224/infusion-pumps-market/

The global infusion pump market is anticipated to grow from USD 9.4 billion in 2020 to USD 18.6 billion by 2029, at a CAGR of 8.1 % during the forecast period.

Surgical Navigation Systems Market

https://exactitudeconsultancy.com/reports/3052/surgical-navigation-systems-market/

The global surgical navigation systems market size is expected to grow at more than 6.3% CAGR from 2022 to 2029. It is expected to reach above USD 2,300 million by 2029 from USD 800 million in 2020.

Controlled Release Drug Delivery Market

https://exactitudeconsultancy.com/reports/3477/controlled-release-drug-delivery-market/

The global controlled release drug delivery market size is expected to grow at 7.8% CAGR from 2022 to 2029. It is expected to reach above USD 78.41 billion by 2029 from USD 39.88 billion in 2020.

Nuclear Imaging Equipment Market

https://exactitudeconsultancy.com/reports/5639/nuclear-imaging-equipment-market/

The global Nuclear Imaging Equipment Market size is USD 2.60 billion in 2020 and is expected to grow till USD 4.43 billion by 2029, at a Compounded annual growth rate (CAGR) of 6.31%.

Dental Consumables Market

https://exactitudeconsultancy.com/reports/2464/dental-consumables-market/

The global dental consumables market is expected to grow at 10.5% CAGR from 2019 to 2028. It is expected to reach above USD 64.37 billion by 2028 from USD 26.21 billion in 2019.


Irfan Tamboli (Head of Sales)
Phone: + 1704 266 3234
Email: sales@exactitudeconsultancy.com

Primary Logo

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Progressive Reports October 2024 Results

MAYFIELD VILLAGE, OHIO, Nov. 15, 2024 (GLOBE NEWSWIRE) — The Progressive Corporation PGR today reported the following results for the month ended October 31, 2024:

  October
(millions, except per share amounts and ratios; unaudited)   2024       2023     Change
Net premiums written $ 6,577.8     $ 5,528.8     19 %
Net premiums earned $ 6,387.0     $ 5,383.2     19 %
Net income $ 408.2     $ 406.0     1 %
Per share available to common shareholders $ 0.69     $ 0.68     1 %
Total pretax net realized gains (losses) on securities $ (88.0 )   $ (87.1 )   1 %
Combined ratio   94.1       91.7     2.4 pts.
Average diluted equivalent common shares   587.7       587.6     0 %
  October 31,
(thousands; unaudited) 2024   2023   % Change
Policies in Force          
Personal Lines          
Agency – auto 9,580.9   8,336.4   15
Direct – auto 13,653.0   11,142.2   23
Total personal auto 23,233.9   19,478.6   19
Total special lines 6,504.4   5,964.4   9
Total Personal Lines 29,738.3   25,443.0   17
Total Commercial Lines 1,140.7   1,108.5   3
Total Property business 3,485.3   3,046.2   14
Companywide Total 34,364.3   29,597.7   16
           

See Progressive’s complete monthly earnings release, including the “Monthly Commentary,” for additional information.

About Progressive

Progressive Insurance® makes it easy to understand, buy and use car insurance, home insurance, and other protection needs. Progressive offers choices so consumers can reach us however it’s most convenient for them — online at progressive.com, by phone at 1-800-PROGRESSIVE, via the Progressive mobile app, or in-person with a local agent.

Progressive provides insurance for personal and commercial autos and trucks, motorcycles, boats, recreational vehicles, and homes; it is the second largest personal auto insurer in the country, a leading seller of commercial auto, motorcycle, and boat insurance, and one of the top 15 homeowners insurance carriers. 

Founded in 1937, Progressive continues its long history of offering shopping tools and services that save customers time and money, like Name Your Price®, Snapshot®, and HomeQuote Explorer®.

The Common Shares of The Progressive Corporation, the Mayfield Village, Ohio-based holding company, trade publicly at NYSE: PGR.

Company Contact:
Douglas S. Constantine
(440) 395-3707
investor_relations@progressive.com

The Progressive Corporation
300 North Commons Blvd.
Mayfield Village, Ohio 44143
http://www.progressive.com

Download PDF: Progressive October 2024 Complete Earnings Release


Primary Logo

Market News and Data brought to you by Benzinga APIs

Are Trust Deeds A More Secure Alternative To Real Estate Syndicates?

For investors seeking a more secure and reliable alternative to real estate syndication, trust deeds may potentially offer a flexible and low-risk investment with the promise of high returns, but without the hassle of property management.

A trust deed is an agreement between a borrower and a lender to have a private loan secured by real estate. Trust deed investors act as the bank, earning passive income through interest rate payments. This type of investment is facilitated by a mortgage broker and loan servicing agent, such as Ignite Funding.

Benefits Of Trust Deed Investing Over Syndication

Trust deeds are an often-overlooked investment opportunity, despite the many advantages they have over real estate syndicates. One of the key benefits is the higher level of security they offer. While syndication involves pooling funds to purchase and collectively manage properties, trust deed investors hold a secured interest in a specific property, which limits risk as they have the right to foreclose if the borrower defaults on the loan. Furthermore, in the case of “first” trust deeds, the deed holder is the first to get paid back in the event of a default, giving investors an added layer of security.

There is also a greater degree of transparency when opting for trust deed investments over syndications, as investors are able to conduct thorough due diligence on the underlying property. This transparency, along with fixed interest rates and regular monthly payments, helps ensure a stable and reliable income stream, making it an attractive option for anyone looking to diversify their investment portfolio.

Trust deed investors also have more control, as they can choose specific properties to invest in and therefore tailor their own real estate investment strategy. They also have more flexibility as they can choose the loan and terms that suit their objectives. This type of control and adaptability is not something you typically get with syndication.

Additionally, by earning interest on the loan amount, trust deeds often yield higher returns, and can potentially be more profitable than traditional syndications and other passive investments.

How To Maximize Returns With Trust Deeds

To optimize returns, it is important to choose a reputable mortgage broker with a strong track record. Partnering with a reliable company such as Ignite Funding can boost your chances of reaping a high return on investment. They can help you carry out due diligence on both the property and borrower, which is a crucial step in trust deed investment.

Prudent investors will also diversify their investments across multiple properties or loan types in order to mitigate risk. This can help protect their investments against market fluctuations and balance potential returns with effective risk management.

If you’re looking for an investment that combines security, transparency and flexibility with the potential for strong returns, trust deeds are an option worth exploring and may offer a compelling alternative to real estate syndications.

Find out more about trust deed investing by visiting the Ignite Funding website or text the word “Benzinga” to 702-919-4281 for additional information.

Ignite Funding, LLC | 6700 Via Austi Parkway, Suite 300, Las Vegas, NV 89119 | P 702.739.9053 | T 702.919.4281 | F 702.922.6700 | NVMBL #311 | AZ CMB-0932150 | | Money invested through a mortgage broker is not guaranteed to earn any interest and is not insured. Prior to investing, investors must be provided applicable disclosure documents.

Featured photo by Oleksandr Pidvalnyi from Pixabay.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs